27 October, 2023: The National Institute for Health and Care Excellence (NICE) has recommended a treatment for advanced Parkinson’s disease that could benefit approximately 900 patients in England. This was the first technology appraisal from NICE to look at a treatment for Parkinson’s disease. Final draft guidance suggests that foslevodopa–foscarbidopa (Produodopa, AbbVie) should be an…
Category: Parkinson’s Disease
Gut bacteria and PD
Could changes in gut bacteria contribute to the development of Parkinson’s disease in those with genetic risk? Via World Parkinson’s Congress: Mutations in the GBA1 gene are one of the most common genetic risk factors associated with Parkinson’s disease (PD). However, it’s important to note that not all people with GBA1 mutations will necessarily develop…
Phase 3 Study Results Compare IPX203 to Immediate-Release Carbidopa/Levodopa for PD
IPX203 demonstrated statistically significant improvement in daily “Good On” time compared to optimised IR CD/LD, with fewer daily doses August 24th, 2023: Amneal Pharmaceuticals, Inc announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safety of IPX203 versus optimised immediate-release carbidopa/levodopa (IR CD/LD) for the treatment of Parkinson’s disease (PD)….
Digital biomarker platform for early and differential diagnosis of Parkinson’s disease
BrainTale has been developing non-invasive, accessible, effective and clinically validated measurement and prediction tools for patients suffering from brain diseases BrainTale, a medtech deciphering white matter to enable better brain care, presented preliminary results demonstrating the effectiveness of its digital biomarker platform for the early and differential diagnosis of Parkinson’s disease. Results were presented during…
Buntanetap in PD faces challenges despite phase III progress
Annovis Bio recently received a positive safety review for the Phase III trial of buntanetap in patients with early Parkinson’s Disease (PD) (NCT05357989) from the Data and Safety Monitoring Board (DSMB). Should buntanetap demonstrate good efficacy and safety profiles in the trial, it could be the first α-synuclein-targeting product to enter the market and one…
Opicapone 50mg in adult levodopa treated PD patients without motor complications
BIAL announces positive results from phase 3 study June 5th, 2023: BIAL announces positive topline results of its phase 3 EPSILON (Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe) study evaluating opicapone 50mg in adult levodopa treated Parkinson’s Disease (PD) patients without motor complications. In the EPSILON study, opicapone 50 mg was found to be statistically significantly…
Can trichloroethylene (TCE) cause Parkinson’s disease (PD)?
In a paper published online on March 14th 2023 in the Journal of Parkinson’s Disease, researchers suggest that a common chemical, TCE, may be a key reason for the dramatic increase in Parkinson’s disease (PD). Lead investigator Ray Dorsey, MD, professor of neurology, University of Rochester, US has called PD “the world’s fastest-growing brain disease,” and said…
Phase 2 Trial of NLY01 in Parkinson’s Disease: Topline results
– This randomised, double-blind, placebo-controlled trial was designed to assess the safety, tolerability, and efficacy of NLY01 in subjects with early, untreated PD. – The primary endpoint, change from baseline in the sum of MDS-UPDRS Parts II and III after 36 weeks of NLY01 treatment, compared with placebo, did not reach statistical significance. – Age was identified as a significant…
Apomorphine Sublingual Film for PD
BIAL announced on 2nd September 2021 that it has entered into an agreement with Sunovion Pharmaceuticals Inc. (Sunovion) whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom. Apomorphine sublingual film (APL-130277) is a novel thin film formulation of…
